Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 4
2009 1
2010 2
2011 5
2012 6
2013 5
2014 1
2015 7
2016 65
2017 79
2018 53
2019 70
2020 80
2021 55
2022 60
2023 54
2024 29

Text availability

Article attribute

Article type

Publication date

PubMed for id: 450439

500 results

Results by year

Filters applied: . Clear all
Page 1
The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC.
Weidhaas JB, Hu C, Komaki R, Masters GA, Blumenschein GR, Chang JY, Lu B, Dicker AP, Bogart JA, Garces YI, Narayan S, Robinson CG, Kavadi VS, Greenberger JS, Koprowski CD, Welsh J, Gore EM, MacRae RM, Paulus R, Bradley JD. Weidhaas JB, et al. Cancer Res Commun. 2023 Oct 11;3(10):2074-2081. doi: 10.1158/2767-9764.CRC-23-0084. Cancer Res Commun. 2023. PMID: 37728512 Free PMC article.
Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer.
Bouhaddou M, Lee RH, Li H, Bhola NE, O'Keefe RA, Naser M, Zhu TR, Nwachuku K, Duvvuri U, Olshen AB, Roy R, Hechmer A, Bolen J, Keysar SB, Jimeno A, Mills GB, Vandenberg S, Swaney DL, Johnson DE, Krogan NJ, Grandis JR. Bouhaddou M, et al. JCI Insight. 2021 Oct 22;6(20):e151982. doi: 10.1172/jci.insight.151982. JCI Insight. 2021. PMID: 34546978 Free PMC article.
The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Weidhaas JB, Harris J, Schaue D, Chen AM, Chin R, Axelrod R, El-Naggar AK, Singh AK, Galloway TJ, Raben D, Wang D, Matthiesen C, Avizonis VN, Manon RR, Yumen O, Nguyen-Tan PF, Trotti A, Skinner H, Zhang Q, Ferris RL, Sidransky D, Chung CH. Weidhaas JB, et al. JAMA Oncol. 2017 Apr 1;3(4):483-491. doi: 10.1001/jamaoncol.2016.5478. JAMA Oncol. 2017. PMID: 28006059 Free PMC article. Clinical Trial.
PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.
Liao HW, Hsu JM, Xia W, Wang HL, Wang YN, Chang WC, Arold ST, Chou CK, Tsou PH, Yamaguchi H, Fang YF, Lee HJ, Lee HH, Tai SK, Yang MH, Morelli MP, Sen M, Ladbury JE, Chen CH, Grandis JR, Kopetz S, Hung MC. Liao HW, et al. J Clin Invest. 2015 Dec;125(12):4529-43. doi: 10.1172/JCI82826. Epub 2015 Nov 16. J Clin Invest. 2015. PMID: 26571401 Free PMC article.
500 results